TABLE 1.
Baseline characteristics
| Cohort 1 225 mg (n = 6) | Cohort 2 600 mg (n = 6) | |
|---|---|---|
| Age, years | 23 (21‐26) | 24 (22‐44) |
| Sex, n female (%) | 2 (33) | 2 (33) |
| Race or ethnicity a , n (%) | ||
| Mixed | 0 (0) | 1 (17) |
| White | 6 (100) | 5 (83) |
| BMI | 26 (24‐30) | 25 (22‐30) |
| Days between symptom onset and dosing | 5 (2‐8) | 5 (3‐5) |
| Positive viral culture, n (%) | 4 (67) | 0 |
| Positive qPCR result, n (%) | 6 (100) | 6 (100) |
| Viral load by qPCR b , mean (SD) | 7.3 (1.0) | 6.6 (1.6) |
| COVID‐19‐related symptom score c | 10.5 (4‐15) | 11.0 (7‐18) |
Note: Data are presented as median (range) unless indicated otherwise.
Abbreviations: BMI, body mass index; qPCR, quantitative polymerase chain reaction, SD, standard deviation.
a
Self‐reported race or ethnicity of patients, who could choose from multiple categories.
b
Viral load expressed as log10 copies/mL.
c
Possible range of aggregated COVID‐19‐related symptom score: 0‐40.